Dedicated to improving the lives of individuals with eosinophilic gastrointestinal disorders
CEGIR Mission Statement
The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is dedicated to improving the lives of individuals with eosinophilic gastrointestinal disorders through innovative research, clinical expertise and education via collaborations between scientists, health care providers, patients, and professional organizations.
Join One of Our Research Studies
Participants make it possible for researchers to find new treatments, speed diagnosis, and improve the lives of those affected by rare diseases
Find a Study
RDCRN Publishes First-Ever Annual Report
Read about research consortium achievements, early career investigators, patients and patient advocacy groups, and other network accomplishments.
Rare Research Report: July 2026
Each month, we share summaries of recent Rare Diseases Clinical Research Network grant-funded publications. Catch up on RDCRN research for July 2026.
Dupilumab Improves Outcomes for Individuals with Eosinophilic Gastritis
A new study from the Consortium of Eosinophilic Gastrointestinal Disease Researchers shows that dupilumab improves outcomes in eosinophilic gastritis.
